P
Polaryx Therapeutics, Inc.
PLYXCIK 0002075320NasdaqEmerging GrowthPharmaceutical PreparationsWyomingFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-8.98M
Total Assets
$5.17M
Equity
$4.57M
Shares Out
47.34M
Op. Cash Flow
$-3.94M
Business
Polaryx Therapeutics, Inc. is a publicly listed company in Pharmaceutical Preparations, incorporated in Wyoming. Common stock trades on Nasdaq under the ticker PLYX.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Research and development expenses | 6 | 3 | |
| General and administrative expenses | 2 | 2 | |
| Total operating expenses | 8 | 4 | |
| Operating loss | −8 | −4 | |
| Other expense direct listing offering costs | −1 | — | |
| Other expense recapitalization of common stock | — | −26 | |
| Net loss and comprehensive loss | −9 | −30 | |
| Net loss per share basic | −0.2 | −0.89 | |
| Net loss per share diluted | −0.2 | −0.89 | |
| Weighted average common shares outstanding basic | 45 | 34 | |
| Weighted average common shares outstanding diluted | 45 | 34 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 5 | 5 | — | |
| Prepaid expenses | — | 380,000 | — | |
| Other current assets | 27,000 | — | — | |
| Total current assets | 5 | 5 | — | |
| Total assets | 5 | 5 | — | |
| Accounts payable | 470,000 | 72,000 | — | |
| Accrued expenses and other current liabilities | 21,000 | 87,000 | — | |
| Total current liabilities | 605,000 | 289,000 | — | |
| Total liabilities | 605,000 | 289,000 | — | |
| Commitments and contingencies (Note 9) | — | — | — | |
| Preferred stock: $0.0001 par value, 40,000,000 shares authorized; 0 and 0 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — | — | |
| Common stock: $0.0001 par value; 560,000,000 shares authorized; 47,343,297 and 41,151,571 shares issued and outstanding at December 31, 2025 and 2024, respectively | 5,000 | 4,000 | — | |
| Additional paid-in capital | 104 | 95 | — | |
| Accumulated deficit | −100 | −91 | — | |
| Total stockholders equity | 5 | 5 | 1 | |
| Total liabilities and stockholders equity | 5 | 5 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Stock-based compensation expense | 5 | 2 | |
| Accounts payable | 398,000 | −401,000 | |
| Due to related party | −39,000 | −220,000 | |
| Accrued expenses related party | 23,000 | — | |
| Accrued expenses and other current liabilities | −66,000 | — | |
| Net cash flows used in operating activities | −4 | −3 | |
| Proceeds from short-term debt related party | — | 65,000 | |
| Repayment of short-term debt related party | — | −193,000 | |
| Payments related to issuance of common stock | −27,000 | — | |
| Proceeds from issuance of common stock | 4 | 7 | |
| Net cash flows provided by financing activities | 4 | 7 | |
| Net increase (decrease) in cash and cash equivalents | 522,000 | 5 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro